Hypoxia-Conditioned Mesenchymal Stem Cells (HC-MSC)-Derived Secretome Gel Induce IL-10 to Improve Diabetic Foot Ulcers via Reduced NF-κB p65 Gene Expression: A Randomized Controlled Trial

Background: Diabetic foot ulcers (DFUs) are a serious complication of diabetes mellitus, often leading to severe outcomes. Given the limitations of current treatments, other strategies are needed to address this gap. Recently, the administration of hypoxia-conditioned mesenchymal stem cells (HC-MSC) secretome has shown promise in treating DFUs, particularly in improving wound healing. This study aims to evaluate the efficacy of HC-MSC-derived secretome gel in treating DFUs by assessing its impact on inflammatory biomarkers, specifically IL-10 and NF-κB p65 gene expression. Methods and Results: This randomized, prospective, controlled clinical trial included 16 patients with type 2 diabetes mellitus (T2DM) and Grade 2–3 DFUs. A control group (n=8) was treated with a placebo/base gel, and an intervention group was treated with HC-MSC-derived secretome gel produced by the Stem Cell and Cancer Research Center, Indonesia. The clinical wound volume, IL-10, and NF-κB p65 were assessed pre- and post-treatment. The relative quantification (RQ) of IL-10 showed a significant increase in the intervention group on Day 7 after treatment compared to the placebo group (mean difference of 1.12, P<0.001), indicating an enhanced anti-inflammatory response. The RQ of NF-κB p65 gene expression significantly decreased in the intervention group (mean difference of 0.488, P=0.001), suggesting reduced inflammatory signaling. These results correlate with improved wound healing in the intervention group, evidenced by reductions in wound volume (mean difference of 0.826 cm3, P=0.002) on Day 7 after treatment. Conclusion: HC-MSC-derived secretome gel significantly enhanced IL-10 expression and reduced NF-κB p65 gene expression in DFUs, improving wound healing outcomes. This approach shows promise as an alternative to conventional treatments. Further research is needed to understand the mechanisms involved.

Publication Details

Journal
International Journal of Biomedicine
Published
2025-03-05
DOI
https://doi.org/10.21103/article15(1)_oa4
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hypoxia-Conditioned Mesenchymal Stem Cells (HC-MSC)-Derived Secretome Gel Induce IL-10 to Improve Diabetic Foot Ulcers via Reduced NF-κB p65 Gene Expression: A Randomized Controlled Trial

International Journal of Biomedicine
Mesenchymal stem cell research
article

Hypoxia-Conditioned Mesenchymal Stem Cells (HC-MSC)-Derived Secretome Gel Induce IL-10 to Improve Diabetic Foot Ulcers via Reduced NF-κB p65 Gene Expression: A Randomized Controlled Trial

article en

Abstract

Background: Diabetic foot ulcers (DFUs) are a serious complication of diabetes mellitus, often leading to severe outcomes. Given the limitations of current treatments, other strategies are needed to address this gap. Recently, the administration of hypoxia-conditioned mesenchymal stem cells (HC-MSC) secretome has shown promise in treating DFUs, particularly in improving wound healing. This study aims to evaluate the efficacy of HC-MSC-derived secretome gel in treating DFUs by assessing its impact on inflammatory biomarkers, specifically IL-10 and NF-κB p65 gene expression. Methods and Results: This randomized, prospective, controlled clinical trial included 16 patients with type 2 diabetes mellitus (T2DM) and Grade 2–3 DFUs. A control group (n=8) was treated with a placebo/base gel, and an intervention group was treated with HC-MSC-derived secretome gel produced by the Stem Cell and Cancer Research Center, Indonesia. The clinical wound volume, IL-10, and NF-κB p65 were assessed pre- and post-treatment. The relative quantification (RQ) of IL-10 showed a significant increase in the intervention group on Day 7 after treatment compared to the placebo group (mean difference of 1.12, P<0.001), indicating an enhanced anti-inflammatory response. The RQ of NF-κB p65 gene expression significantly decreased in the intervention group (mean difference of 0.488, P=0.001), suggesting reduced inflammatory signaling. These results correlate with improved wound healing in the intervention group, evidenced by reductions in wound volume (mean difference of 0.826 cm3, P=0.002) on Day 7 after treatment. Conclusion: HC-MSC-derived secretome gel significantly enhanced IL-10 expression and reduced NF-κB p65 gene expression in DFUs, improving wound healing outcomes. This approach shows promise as an alternative to conventional treatments. Further research is needed to understand the mechanisms involved.

International Journal of BiomedicineVol. 15(1)
Good health and well-being
Openalex Percentile: Top 94%
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Hypoxia-Conditioned Mesenchymal Stem Cells (HC-MSC)-Derived Secretome Gel Induce IL-10 to Improve Diabetic Foot Ulcers via Reduced NF-κB p65 Gene Expression: A Randomized Controlled Trial · International Journal of Biomedicine (2025) | TGRS Research Map | TGRS